egotux® caps 25mg/cap
genepharm ae 18 ΧΛΜ. Λ. ΜΑΡΑΘΩΝΟΣ, 15351 ΠΑΛΛΗΝΗ ΑΤΤΙΚΗΣ 6039336 - sunitinib - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 25mg/cap - sunitinib 25mg - sunitinib
egotux® caps 37.5mg/cap
genepharm ae 18 ΧΛΜ. Λ. ΜΑΡΑΘΩΝΟΣ, 15351 ΠΑΛΛΗΝΗ ΑΤΤΙΚΗΣ 6039336 - sunitinib - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 37.5mg/cap - sunitinib 37,5mg - sunitinib
egotux® caps 50mg/cap
genepharm ae 18 ΧΛΜ. Λ. ΜΑΡΑΘΩΝΟΣ, 15351 ΠΑΛΛΗΝΗ ΑΤΤΙΚΗΣ 6039336 - sunitinib - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 50mg/cap - sunitinib 50mg - sunitinib
cetrorelix/sun 0.25mg/ml ενεσιμο διαλυμα σε προγεμισμενη συριγγα
sun pharmaceutical industries europe b.v., hoofddorp, nether (0000009552) polarisavenue 87, 2132 jh hoofddorp - cetrorelix - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ ΣΕ ΠΡΟΓΕΜΙΣΜΕΝΗ ΣΥΡΙΓΓΑ - 0.25mg/ml - 0120287856 cetrorelix 0.250000 mg - cetrorelix
sutirem 12.5mg capsule,hard
remedica ltd (0000003171) aharnon str., lemesos, 3056 - sunitinib - capsule,hard - 12.5mg - sunitinib (8000003189) 12,5mg
sutirem 37.5mg capsule,hard
remedica ltd (0000003171) aharnon str., lemesos, 3056 - sunitinib - capsule,hard - 37.5mg - sunitinib (8000003189) 37,5mg
sutirem 25mg capsule,hard
remedica ltd (0000003171) aharnon str., lemesos, 3056 - sunitinib - capsule,hard - 25mg - sunitinib (8000003189) 25mg
sutirem 50mg capsule,hard
remedica ltd (0000003171) aharnon str., lemesos, 3056 - sunitinib - capsule,hard - 50mg - sunitinib (8000003189) 50mg
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Αντινεοπλασματικοί παράγοντες - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
sun-de3® oral.sol 25000 iu/ml
nassington ltd, cyprus Ιπποκράτους 3Α,, 2006 Λευκωσία - cholecalciferol concentrate - oral.sol (ΠΟΣΙΜΟ ΔΙΑΛΥΜΑ) - 25000 iu/ml - cholecalciferol concentrate 25mg - colecalciferol